Lupin has received its shareholders approval to raise up to Rs 7,500 crore through issue of securities. The shareholders also approved reappointment of Desh Bandhu Gupta as Executive Chairman of the company for five years with effect from January 1, 2016. The company has already received its board nod for the same last month.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.